Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

FDA Approvals, News & Updates

Recent FDA Drug Approvals: A Directory for Patients

Blenrep Approved for the Treatment of Relapsed or Refractory Multiple Myeloma
A drug called Blenrep (belantamab mafodotin-blmf) was recently approved by the Food and Drug Administration (FDA) for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies (including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent). Read More ›

Imbruvica/Rituximab Combo Approved for First-Line Leukemia
The Food and Drug Administration (FDA) has expanded the use of the anticancer drug Imbruvica (ibrutinib) to be used in combination with rituximab for the treatment of the most common type of leukemia in adults, chronic lymphocytic leukemia (CLL), or its variant called small lymphocytic lymphoma (SLL). Read More ›

Opdivo plus Yervoy Immunotherapy Combination Approved for Patients with Liver Cancer
Opdivo (nivolumab) given in combination with Yervoy (ipilimumab) is now approved by the Food and Drug Administration (FDA) for the treatment of patients with liver cancer, or hepatocellular carcinoma (HCC), who have already been treated with the chemotherapy drug sorafenib. Read More ›

Immunotherapy Combination Provides New Hope for Patients with Certain Type of Non–Small-Cell Lung Cancer
A treatment combination containing the immunotherapy drugs Opdivo (nivolumab) and Yervoy (ipilimumab) received 2 approvals in non–small-cell lung cancer (NSCLC) in the past year. Read More ›

New Treatment Option for Certain Type of Advanced Bile Duct Cancer
Patients with advanced bile duct cancer, or cholangiocarcinoma (CCA), have few treatment options and a generally poor prognosis. But now, a new medication called Pemazyre (pemigatinib) has been approved by the Food and Drug Administration (FDA) for the treatment of CCA that has spread to other parts of the body or that cannot be removed by surgery, providing a new treatment option for these patients, and perhaps a better outlook for their future. Read More ›

Tazverik: Approved for Advanced Epithelioid Sarcoma and Follicular Lymphoma

New Targeted Therapy for Patients with Metastatic Triple-Negative Breast Cancer
People with triple-negative breast cancer (TNBC) that has spread to other parts of the body (metastatic) now have a new treatment option called Trodelvy (sacituzumab govitecan-hziy). This drug was recently approved by the Food and Drug Administration (FDA) for use specifically in adult patients with metastatic TNBC who have already received at least 2 previous treatments for their cancer. Read More ›

Zejula Approved as Once-Daily Treatment Option in Women with Advanced Ovarian Cancer
Women with advanced ovarian cancer now have a new once-daily treatment option. In April 2020, the Food and Drug Administration (FDA) approved Zejula (niraparib) for the maintenance treatment of all women with advanced ovarian cancer (including epithelial cancer, fallopian tube cancer, and primary peritoneal cancer) who have responded well to first-line chemotherapy. Maintenance therapy is the treatment of cancer with medication, typically following a first round of treatment (in this case, platinum-based chemotherapy). Read More ›

Gavreto Second Drug FDA Approved for Patients with Metastatic Lung Cancer and RET Fusions
In September 2020, the FDA approved a second drug for the treatment of patients with lung cancer and RET fusions, improving the treatment options available today for patients with this type of lung cancer. Read More ›

Page 8 of 16